TOKYO, December 6 , 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today applied for selection of the "Prime Market" segment of the Tokyo Stock Exchange, Inc. ("TSE") as its listing market as determined at the Board of Directors Meeting held on November 19, 2021.
Astellas received the results of the initial assessment made by the TSE on July 9, 2021, confirming Astellas' compliance with the listing requirements for the "Prime Market" in the new market segments that will be introduced on April 4, 2022 by the TSE.
Click below for a copy of the full press release
Astellas Pharma Inc. published this content on 06 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 December 2021 07:11:04 UTC.